ADPT Adaptive Biotechnologies Corp
Price (delayed)
$7.52
Market cap
$1.12B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.08
Enterprise value
$1.29B
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the
Highlights
ADPT's EPS is up by 31% year-on-year and by 19% since the previous quarter
The company's net income rose by 29% YoY and by 18% QoQ
The quick ratio has declined by 38% year-on-year and by 17% since the previous quarter
ADPT's equity is down by 34% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of ADPT
Market
Valuations
Earnings
Shares outstanding
148.58M
Market cap
$1.12B
Enterprise value
$1.29B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.47
Price to sales (P/S)
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.2
Revenue
$178.96M
Gross profit
$106.88M
Operating income
-$162.55M
Net income
-$159.49M
EBIT
-$147.91M
EBITDA
-$123.38M
Free cash flow
-$98.88M
Per share
Balance sheet
Liquidity
EPS
-$1.08
EPS diluted
-$1.08
Free cash flow per share
-$0.67
Book value per share
$1.37
Revenue per share
$1.22
TBVPS
$2.83
Total assets
$539.38M
Total liabilities
$336.89M
Debt
$222.67M
Equity
$202.71M
Working capital
$185.7M
Debt to equity
1.1
Current ratio
2.89
Quick ratio
2.72
Net debt/EBITDA
-1.39
Margins
Efficiency
Dividend
EBITDA margin
-68.9%
Gross margin
59.7%
Net margin
-89.1%
Operating margin
-90.8%
Return on assets
-27.7%
Return on equity
-67.7%
Return on invested capital
-27.8%
Return on capital employed
-33.5%
Return on sales
-82.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADPT stock price
How has the Adaptive Biotechnologies stock price performed over time
Intraday
1.21%
1 week
-10.69%
1 month
-8.96%
1 year
141.8%
YTD
25.44%
QTD
1.21%
Financial performance
How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$178.96M
Gross profit
$106.88M
Operating income
-$162.55M
Net income
-$159.49M
Gross margin
59.7%
Net margin
-89.1%
ADPT's net margin is up by 33% year-on-year and by 19% since the previous quarter
Adaptive Biotechnologies's operating margin has increased by 32% YoY and by 19% QoQ
The company's net income rose by 29% YoY and by 18% QoQ
Adaptive Biotechnologies's operating income has increased by 28% YoY and by 19% QoQ
Growth
What is Adaptive Biotechnologies's growth rate over time
Valuation
What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
5.47
P/S
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.2
ADPT's EPS is up by 31% year-on-year and by 19% since the previous quarter
ADPT's P/B is 87% above its last 4 quarters average of 2.9 and 10% above its 5-year quarterly average of 4.9
ADPT's equity is down by 34% year-on-year and by 9% since the previous quarter
ADPT's price to sales (P/S) is 73% lower than its 5-year quarterly average of 22.8 but 61% higher than its last 4 quarters average of 3.8
The revenue has grown by 5% YoY
Efficiency
How efficient is Adaptive Biotechnologies business performance
ADPT's return on sales is up by 33% year-on-year and by 20% since the previous quarter
The ROIC has grown by 15% from the previous quarter and by 14% YoY
Adaptive Biotechnologies's ROA has increased by 14% from the previous quarter and by 10% YoY
The ROE has decreased by 12% YoY but it has increased by 9% QoQ
Dividends
What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADPT.
Financial health
How did Adaptive Biotechnologies financials performed over time
The total assets is 60% more than the total liabilities
The current ratio has contracted by 38% YoY and by 18% from the previous quarter
The quick ratio has declined by 38% year-on-year and by 17% since the previous quarter
ADPT's debt is 10% greater than its equity
ADPT's debt to equity is up by 49% year-on-year and by 10% since the previous quarter
ADPT's equity is down by 34% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.